Biofrontera AG (BFRA): Price and Financial Metrics


Biofrontera AG (BFRA): $2.67

-0.28 (-9.49%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

BFRA Stock Price Chart Interactive Chart >

Price chart for BFRA

BFRA Price/Volume Stats

Current price $2.67 52-week high $7.54
Prev. close $2.95 52-week low $2.09
Day low $2.60 Volume 4,900
Day high $3.10 Avg. volume 27,512
50-day MA $3.03 Dividend yield N/A
200-day MA $4.94 Market Cap 75.72M

Biofrontera AG (BFRA) Company Bio


Biofrontera AG, a biopharmaceutical company, primarily focuses on the discovery, development, and distribution of dermatological drugs and dermatologically tested cosmetics for the treatment and care of diseased skin. Biofrontera AG was founded in 1997 and is based in Leverkusen, Germany.


BFRA Latest News Stream


Event/Time News Detail
Loading, please wait...

BFRA Latest Social Stream


Loading social stream, please wait...

View Full BFRA Social Stream

Latest BFRA News From Around the Web

Below are the latest news stories about Biofrontera AG that investors may wish to consider to help them evaluate BFRA as an investment opportunity.

Biofrontera AG decides to delist ADS from Nasdaq to reduce complexity and costs

Leverkusen, Germany, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Biofrontera AG (the “Company”) (Nasdaq: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, decided today its American Depositary Shares (“ADS”) should be delisted from the Nasdaq Capital Market (“Nasdaq”) and its reporting obligations with the Securities and Exchange Commission (“SEC”) should be deregistered and terminated. The main purpose of the delisting is to reduce complexity in financial reporting and adm

Yahoo | February 14, 2022

Biofrontera Stock Plunges After Announcing Nasdaq Delisting

By Sam Boughedda

Yahoo | February 14, 2022

Why Are Biofrontera Shares Rising Today?

Biofrontera Inc (NASDAQ: BFRI ) has provided an update on the patient recruitment for the Phase 3 study for superficial basal cell carcinoma (sBCC) with Ameluz photodynamic therapy (PDT) combined with BF-RhodoLED lamp in the U.S. To date, 70% of the planned 186 patients have been enrolled in the study. Patient recruitment for this study has been ongoing since 2018, with the Full story available on Benzinga.com

Benzinga | February 1, 2022

Biofrontera spikes after recruitment update on late-stage trial for skin cancer

Biofrontera <> is trading sharply higher after announcing that the company enrolled 70% of patients in its Phase 3 study for Ameluz photodynamic therapy in superficial basal…

Seeking Alpha | February 1, 2022

Biofrontera, Synaptogenix top healthcare gainers; while Sio Gene, Anavex among losers

Biofrontera (BFRI) +14%. Synaptogenix (SNPX) +11%. Sio Gene Therapies (SIOX) -19%. Anavex Life Sciences (AVXL) -16%.

Seeking Alpha | February 1, 2022

Read More 'BFRA' Stories Here

BFRA Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year -21.47%
3-year -73.67%
5-year N/A
YTD -10.10%
2021 -59.26%
2020 N/A
2019 0.00%
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7728 seconds.